See also
References
Ang CW, Jacobs BC, Laman JD. (2004) The Guillain-Barre Syndrome: a true case of molecular mimicry. Trends in Immunology. 25(2):61-66.
Harel M and Yehuda Sheonfeld. (2005) Intravenous Immunoglobulin and Guillain-Barre Syndrome. Clinical Reviews in Allergy & Immunology. 29:281-287.
Ho TW, McKhann GM, Griffin JW. (1998) Human Autoimmune Neuropathies. Annu. Rev. Neurosci. 21:187-226.
Hughes RAC, Allen D, Makowska A, Gregson NA. (2006) Pathogenesis of chronic inflammatory demyelinating polyradiculoneuropathy. Journal of the Peripheral Nervous System. 11:30-46.
Janeway, CA, Travers P, Walport M, Shlomchik MJ. (2005) Immunobiology: The immune system in health and disease, 6th edition. New York: Garland Publishing.
Koga M, Gilbert M, Takahashi M, Li J, Koike S, Hirata K, Yuki N. (2006) Comprehensive analysis of bacterial risk factors for the development of Guillain-Barre Syndrome after Campylobacter jejuni infection. Journal of Infectious Disease. 193:547-55.
Kuwabara S. (2004) Guillain-Barre Syndrome: epidemiology, pathophysiology, and management. Drugs. 64(6):597-610.
Moran PM, Annuk H, Prendergast MM. (2005) Antibodies induced by ganglioside-mimicking Campylobacter jejuni liooligosaccharides recognise epitopes at the nodes of Ranvier. Journal of Neuroimmunology. 165:179-185.
Neisser A, Schwerer B, Bernheimer H, Moran AP. (2000) Ganglioside-induced antiganglioside antibodies from a neuropathy patient cross-react with lipopolysaccharides of Campylobacter jejuni associated Guillain-Barre syndrome. Journal of Neuroimmunolgy. 102:85-88.
Shahar E. (2006) Current therapeutic options in severe Guillain-Barre Syndrome. Clinical Neuropharmacology. 29(1):45-51.
Yuki N. (2005) Carbohydrate mimicry: a new paradigm of autoimmune diseases. Current Opinion in Immunology. 17:577-582.